Novartis stacks more positive PhIII data on Cosentyx franchise — eyeing approval in non-radiographic axial spondyloarthritis

Days ago Novartis posted a brief note on positive 16-week data about Cosentyx’s effects on non-radiographic axial spondyloarthritis, opening the door to an EMA submission in the indication. Now the pharma giant says it has the 52-week win needed to take to FDA regulators, too.